KADMON

Amber Specialty Pharmacy Selected by Kadmon to Dispense REZUROCK™ (belumosudil) Tablets for Chronic Graft-Versus-Host Disease Patients

Retrieved on: 
Monday, August 9, 2021
Biotechnology, General Health, Health, Stem Cells, Pharmaceutical, Fibrosis, Joint, Hy-Vee, FDA, Mouth, Failure, Person, B cell, URAC, Haematopoietic system, Skin, Esophagus, Accreditation Commission for Health Care, Regulation of tobacco by the U.S. Food and Drug Administration, Partnership, Hematopoietic stem cell transplantation, Liver, Pharmacy, Patient, Gastrointestinal tract, Adult, ROCK2, Lung, Tablet, Eye, ACHC, Inflammation, Food, Hospital, Amber Specialty Pharmacy, Kadmon, AMBER SPECIALTY PHARMACY, KADMON

Amber Specialty Pharmacy announces that it will begin dispensing REZUROCK (belumosudil) tablets for chronic graft-versus-host disease (cGVHD) to patients throughout the United States.

Key Points: 
  • Amber Specialty Pharmacy announces that it will begin dispensing REZUROCK (belumosudil) tablets for chronic graft-versus-host disease (cGVHD) to patients throughout the United States.
  • Amber Specialty Pharmacy is one of three specialty pharmacies selected by Kadmon to dispense REZUROCK as part of a limited distribution network.
  • Amber Specialty Pharmacy is a pioneer and leader in the specialty pharmacy industry with over 23 years of experience providing specialized care for persons with chronic, complex medical conditions.
  • Amber Specialty Pharmacy has built an outstanding reputation by providing personalized support and quality clinical care to patients and families.

Iktos Announces Collaboration with Kadmon to Use AI for New Drug Design

Retrieved on: 
Tuesday, May 18, 2021
Other Manufacturing, Technology, Medical devices, Chemicals, Plastics, Software, Manufacturing, Biotechnology, Pharmaceutical, Health, Data management, Health sciences, Pharmaceutical sciences, Life sciences, Medicinal chemistry, Drug discovery, Design of experiments, Drug design, Medication, Intel X99, Kadmon, Iktos, Kadmon, IKTOS, KADMON

b'Iktos, a company specializing in Artificial Intelligence for new drug design, today announced that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, pursuant to which, Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology will be used to enable the rapid and cost-effective design of novel drug candidates for an undisclosed Kadmon drug discovery program.

Key Points: 
  • b'Iktos, a company specializing in Artificial Intelligence for new drug design, today announced that it has entered into a Research Collaboration Agreement with Kadmon, a clinical-stage biopharmaceutical company based in New York, USA, pursuant to which, Iktos\xe2\x80\x99s generative modelling artificial intelligence (AI) technology will be used to enable the rapid and cost-effective design of novel drug candidates for an undisclosed Kadmon drug discovery program.
  • Kadmon is expanding and integrating novel drug discovery platforms, with the aim of identifying and developing new product candidates for significant unmet medical needs.
  • Iktos\xe2\x80\x99 technology automatically designs virtual novel molecules that have all of the characteristics of a successful drug molecule.
  • In early-stage discovery projects, Iktos\xe2\x80\x99 technology allows the design of novel hits with optimal protein-ligand interactions, as predicted by molecular modelling technology.